Celgene Corp. buy matumba
Start price
22.10.11
/
50%
€24.05
Target price
28.12.11
€26.08
Performance (%)
8.41%
End price
28.12.11
€26.08
Summary
This prediction ended on 28.12.11 with a price of €26.08. With a performance of 8.41%, the BUY prediction by matumba for Celgene Corp. closed with a slight gain. matumba has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Celgene Corp. | - | - | - | - |
| iShares Core DAX® | -1.212% | 1.925% | 17.589% | 68.786% |
| iShares Nasdaq 100 | -4.714% | -1.810% | 0.450% | 100.066% |
| iShares Nikkei 225® | -2.976% | -2.660% | 10.156% | 43.024% |
| iShares S&P 500 | -2.744% | -0.448% | 0.320% | 63.222% |
Comments by matumba for this prediction
In the thread Celgene Corp. diskutieren
risikobereit?
Revlimid Präparat gegen Krebs soll 2012 ein Umsatzplus von 30% bringen (3,15MRD Dollar)
Europ. Arzneimittelagentur hat sich positiv geäußert- dies ermögl. gute Chancen
(Zielkurs erreicht)


